RTI Biologics announced leadership changes
Robert P. Jordheim has joined the company as executive vice president and chief financial officer , Thomas F. Rose, executive vice president, has transitioned from the role of chief financial officer to RTI’s chief operations officer, Caroline A. Hartill has been named executive vice president and chief scientific officer, and Roger W. Rose has been named executive vice president and chief commercial officer.[break]
Mr. Jordheim joined the company on June 21, 2010 as executive vice president and CFO, and will oversee all aspects of finance for the company. He has 24 years of progressive corporate finance experience, including 17 years with Medtronic, Inc. Most recently, he served as vice president, finance and business development for Medtronic’s Spinal and Biologics business unit.
Previously, Mr. Jordheim served as vice president, finance for Medtronic’s Surgical Technologies business unit. His tenure with Medtronic also included responsibilities in corporate development and international experience gained through a five-year assignment in Europe. Previous to his tenure at Medtronic, Jordheim served as manager of external reporting at The Fairchild Corporation and an auditor for Deloitte & Touche.
Mr. Jordheim earned a bachelor’s degree in business administration from Southern Methodist University and a master’s degree in business administration from the University of Pittsburgh with a concentration in finance.
Mr. Rose has transitioned from the role of executive vice president and CFO to the newly created position of executive vice president and COO. He joined RTI in May 2002 as vice president and CFO, and was promoted to executive vice president and CFO in February 2008.
Before joining RTI, Mr. Rose served the previous 10 years as vice president and chief financial officer at A.M. Todd Group, based in Kalamazoo, Mich. He earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo.
Ms. Hartill, has been named executive vice president and maintains her role as CSO, which was effective in March 2007. In her role, she oversees all quality assurance and regulatory affairs, as well as all research and development activities.
Ms. Hartill joined RTI in November 2001 and was named vice president of quality assurance and regulatory affairs in January 2003. For 18 years prior, she worked in the areas of technology development and market approvals as a freelance consultant working with many major and start-up biotechnology and medical device companies worldwide.
Ms. Hartill earned a bachelor’s degree with honors in health sciences from Birmingham University Medical School in England, as well as a master’s degree in management from the University of Wolverhampton in England. Hartill has also earned master’s level credits in sterilization science from Manchester University.
Mr. Rose will serve in the newly created position of executive vice president and CCO, with responsibilities for all marketing and distribution activities. He will continue to serve as president of RTI Donor Services, which was effective in February 2008. Within these two roles, Rose is committed to ensuring a meaningful connection between the donation and transplantation communities.
Mr. Rose joined RTI as vice president of donor services in October 2002 and assumed additional responsibility for distribution and marketing in October 2003. Prior to this, Rose spent seven years at Stryker Corporation based in Kalamazoo, Mich., where he held leadership positions in sales and marketing in both the medical and orthopedic divisions. ■